Compositions and methods using microspheres and non-ionic contrast agents
First Claim
1. A substantially spherical microsphere, comprising:
- a biocompatible polymeric material comprising a polymer or copolymer prepared from one or more acrylate monomers,a drug selected from at least one of the following;
daunorubicin, daunomycin, doxorubicin, irinotecan, and topotecan, wherein the concentration of drug is between about 1 mg to about 400 mg of drug per 100 mg of dry microspheres, anda non-ionic contrast agent containing iodine, wherein the concentration of non-ionic contrast agent is between about 100 mg to about 3200 mg iodine per 100 mg of dry microspheres, wherein the non-ionic contrast agent is selected from at least one of the following;
metrizamide, iopamidol, iodixanol, iohexol, ioversol, iopromide, iobitridol, iomeprol, iopentol, iopamiron, ioxilan, iotrolan, iotrol, and combinations thereofwherein the microsphere is swellable in a pharmaceutically acceptable solution and has a diameter of from about 10 μ
m to about 1000 μ
m before swelling wherein the diameter of the microsphere is from about 40 μ
m to about 2000 μ
m after swelling.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.
170 Citations
16 Claims
-
1. A substantially spherical microsphere, comprising:
-
a biocompatible polymeric material comprising a polymer or copolymer prepared from one or more acrylate monomers, a drug selected from at least one of the following;
daunorubicin, daunomycin, doxorubicin, irinotecan, and topotecan, wherein the concentration of drug is between about 1 mg to about 400 mg of drug per 100 mg of dry microspheres, anda non-ionic contrast agent containing iodine, wherein the concentration of non-ionic contrast agent is between about 100 mg to about 3200 mg iodine per 100 mg of dry microspheres, wherein the non-ionic contrast agent is selected from at least one of the following;
metrizamide, iopamidol, iodixanol, iohexol, ioversol, iopromide, iobitridol, iomeprol, iopentol, iopamiron, ioxilan, iotrolan, iotrol, and combinations thereofwherein the microsphere is swellable in a pharmaceutically acceptable solution and has a diameter of from about 10 μ
m to about 1000 μ
m before swelling wherein the diameter of the microsphere is from about 40 μ
m to about 2000 μ
m after swelling. - View Dependent Claims (2, 3, 4, 5, 6, 7, 15)
-
-
8. A substantially spherical microsphere, comprising:
-
a biocompatible polymeric material comprising a polymer or copolymer prepared from one or more acrylate monomers, doxorubicin, wherein the concentration of doxorubicin is between about 1 mg to about 400 mg of drug per 100 mg of dry microspheres, and a non-ionic contrast agent containing iodine, wherein the concentration of non-ionic contrast agent is between about 100 mg to about 3200 mg iodine per 100 mg of dry microspheres, wherein the non-ionic contrast agent is selected from at least one of the following;
metrizamide, iopamidol, iodixanol, iohexol, ioversol, iopromide, iobitridol, iomeprol, iopentol, iopamiron, ioxilan, iotrolan, iotrol, and combinations thereof,wherein the microsphere is swellable in a pharmaceutically acceptable solution and has a diameter of from about 10 μ
m to about 1000 μ
m before swelling wherein the diameter of the microsphere is from about 40 μ
m to about 2000 μ
m after swelling. - View Dependent Claims (9, 10, 11, 12, 13, 14, 16)
-
Specification